Business Context and Reporting Period
Company: Inhibikase Therapeutics, Inc. (IKT)
Filing Type: Form 8-K (Current Report)
Date of Report: June 15, 2021
Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock.
Key Financial Metrics and Offering Details
- Shares Offered: 15,000,000 shares of Common Stock.
- Public Offering Price: $3.00 per share.
- Underwriter Purchase Price: $2.79 per share (7% discount).
- Gross Proceeds: Approximately $45 million.
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to 2,250,000 additional shares.
- Potential Total Proceeds: Approximately $51.75 million if the over-allotment option is exercised in full.
- Representative's Warrant: Option to purchase 750,000 shares at $3.75 per share, exercisable from June 15, 2022, through June 15, 2026.
Note: This filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for these items.
Material Changes and Lock-Up Provisions
The Company entered into an underwriting agreement with ThinkEquity (a division of Fordham Financial Management, Inc.). Key terms include:
- Lock-Up Period: The Company, directors, executive officers, and greater than 5% stockholders agreed not to sell shares for specific periods following the final prospectus date:
- Company and >5% stockholders: 3 months.
- Directors and executive officers: 6 months.
- Closing Date: Expected on or about June 18, 2021, subject to customary conditions.
Outlook, Risks, and Forward-Looking Statements
Management Commentary: The offering is intended to raise capital for the Company's operations. The final prospectus was expected to be filed on or about June 17, 2021.
Risks and Contingencies:
- Clinical Uncertainty: Positive results from early clinical studies are not necessarily predictive of later clinical trial results.
- Market Conditions: Actual results may differ due to market conditions and the satisfaction of closing conditions.
- Forward-Looking Nature: Statements regarding the timing of the closing and potential additional share offerings are subject to risks and uncertainties.
Investor Verification Checklist
- Verify the final closing date of the offering (expected June 18, 2021) and whether the over-allotment option was exercised.
- Review the final prospectus (Form 424(b)) for updated use of proceeds and risk factors.
- Confirm the exact number of shares issued and the net proceeds after deducting underwriting discounts and offering expenses.
- Monitor the Company's cash position post-offering to assess runway for clinical trials.
- Check for any subsequent filings regarding the exercise of the Representative's Warrant.